Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Artivion Inc (AORT)

Artivion Inc (AORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023...

AORT : 20.32 (+1.45%)
Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X...

AORT : 20.32 (+1.45%)
Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the...

AORT : 20.32 (+1.45%)
Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference PR Newswire - Tue Sep 26, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at...

AORT : 20.32 (+1.45%)
Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present...

AORT : 20.32 (+1.45%)
Artivion to Participate in Upcoming Investor Conferences PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...

AORT : 20.32 (+1.45%)
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results PR Newswire - Thu Jul 20, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023...

AORT : 20.32 (+1.45%)
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter PR Newswire - Tue May 23, 2023

/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and...

AORT : 20.32 (+1.45%)
BAX : 40.40 (+2.36%)
Artivion (AORT) Q1 Earnings and Revenues Beat Estimates Zacks - Thu May 4, 2023

Artivion (AORT) delivered earnings and revenue surprises of 166.67% and 2.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AORT : 20.32 (+1.45%)
RWLK : 1.0501 (+6.07%)
Artivion Reports First Quarter 2023 Financial Results PR Newswire - Thu May 4, 2023

First Quarter and Recent Business Highlights: Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022,...

AORT : 20.32 (+1.45%)

Barchart Exclusives

This Option Trade on Adobe Stock Has a Profit Zone Between $430 and $490 Barchart - 26 minutes ago
The price of Adobe (ADBE) stock has pulled back in recent weeks, with the stock looking like it might find support around the $460 level. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot